CAMP4 Therapeutics (CAMP) Stock: Buy, Sell, or Hold?
CAMP - CAMP4 Therapeutics Corporation Common Stock
$3.78
-0.19 (-4.67%)
âŧ
5d:
+17.6%
30d:
-5.63%
90d:
-9.25%
WAIT
LOW Confidence
Analysis Updated: Nov 2, 2026 12:00 AM ET
Earnings: Nov 05, 2026
1d
Get Alerted When CAMP Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: CAMP is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: CAMP is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: CAMP is currently trading at $3.77, which is considered fair relative to its 30-day fair value range of $3.36 to $3.94.
Technical Outlook: Technically, CAMP is in a downtrend. Immediate support is located at $2.96, while resistance sits at $4.15. Short-term momentum is weak, with the stock down 4.7% recently.
Market Sentiment: CAMP scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $10.22 (+170.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CAMP is in a downtrend. Immediate support is located at $2.96, while resistance sits at $4.15. Short-term momentum is weak, with the stock down 4.7% recently.
Market Sentiment: CAMP scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $10.22 (+170.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$3.36 -
$3.94
Company Quality Score
34/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
44.7%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.7%)
- BULLISH: Trading 170.8% below Wall St target ($10.22)
- WARNING: Composite score 34/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$3.36 -
$3.94
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$2.96
Resistance Level
$4.15
Current Trend
Downtrend
Technical data as of
Nov 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.41
Wall Street Target
$10.22
(+170.8%)
Revenue Growth (YoY)
18.8%
Share & Embed Analysis
Last updated: November 02, 2026 8:13 PM ET
Data refreshes hourly during market hours. Next update: 9:13 PM
Data refreshes hourly during market hours. Next update: 9:13 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CAMP showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals IâĻ |
STRONG BUY
32 analysts |
$571 | 37 SELL |
|
ALNY
Alnylam Pharmaceuticals âĻ |
STRONG BUY
30 analysts |
$315 | 41 HOLD |
|
TVTX
Travere Therapeutics Inc |
STRONG BUY
15 analysts |
$75 | 68 BUY |
|
ASND
Ascendis Pharma AS |
STRONG BUY
22 analysts |
$304 | 30 SELL |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$63 | 65 BUY |
